MetaCap

Cellectar Biosciences (CLRB) vs Phio Pharmaceuticals (PHIO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Phio Pharmaceuticals (PHIO) has outperformed Cellectar Biosciences (CLRB) over the past year, losing 41.4% versus a loss of 72.1%. Over five years, PHIO leads with a -99.6% price change compared with -99.6% for CLRB. Cellectar Biosciences is the larger company by market cap ($8.0 million vs $7.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CLRB-72.13%PHIO-41.43%
+53%-12%-78%
Nov 21, 20251 yearNov 20, 2026
CLRB-99.65%PHIO-99.56%
+80%-14%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CLRB versus PHIO key metrics
MetricCLRBPHIO
Share price$0.797$0.656
Market cap$8.00M$7.84M
1-day change-11.50%-8.25%
YTD return-72.98%-37.52%
1-year return-72.13%-41.43%
5-year return-99.63%-99.56%
EPS (TTM)$-2.34$-1.21
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-21.79M$-8.70M
52-week high$4.70$1.88
52-week low$0.7596$0.6395
Distance from 52-week high-83.04%-65.11%
Analyst consensusnonenone
Avg. price target upside+1342.91%+2034.15%
Average volume97.96K106.09K
Shares outstanding10.04M11.95M
Employees116
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PHIO has outperformed CLRB by 30.7 percentage points over the past year.

About Cellectar Biosciences

CLRB stock →

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees

About Phio Pharmaceuticals

PHIO stock →

Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies.

Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees

CLRB vs PHIO FAQ

Which is bigger, Cellectar Biosciences or Phio Pharmaceuticals?

Cellectar Biosciences (CLRB) is larger, with a market capitalization of $8.00M compared with $7.84M for Phio Pharmaceuticals (PHIO).

Which stock has performed better over the past year, CLRB or PHIO?

PHIO returned -41.43% over the past 12 months, compared with -72.13% for CLRB (price return, excluding dividends). Past performance does not predict future results.

Are Cellectar Biosciences and Phio Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons